IBBR Publications
Found 45 results
Filters: Keyword is HIV-1 [Clear All Filters]
.
Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J Immunol. 2014 ;192(3):1100-6.
HIV. Expanding the breadth of an HIV-1 vaccine. Science. 2014 ;346(6215):1290-1.
. Single-cell and deep sequencing of IgG-switched macaque B cells reveal a diverse Ig repertoire following immunization. J Immunol. 2014 ;192(8):3637-44.
. Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies. Nat Struct Mol Biol. 2014 ;21(12):1058-67.
. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6. J Virol. 2014 ;88(5):2426-41.
Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci U S A. 2014 ;111(7):E738-47.
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science. 2013 ;340(6133):751-6.
Internal dynamics of the homotrimeric HIV-1 viral coat protein gp41 on multiple time scales. Angew Chem Int Ed Engl. 2013 ;52(14):3911-5.
. Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc Natl Acad Sci U S A. 2013 ;110(16):6470-5.
Molecular determinants of HIV-1 NCp7 chaperone activity in maturation of the HIV-1 dimerization initiation site. Nucleic Acids Res. 2013 ;41(4):2565-80.
. Structure and dynamics of full-length HIV-1 capsid protein in solution. J Am Chem Soc. 2013 ;135(43):16133-47.
. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012 ;491(7424):406-12.
High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med. 2012 ;4(142):142ra96.
. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J Virol. 2012 ;86(20):11231-41.
Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. PLoS One. 2012 ;7(9):e44241.
Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol. 2012 ;86(10):5844-56.
Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol. 2011 ;18(11):1235-43.
Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol. 2011 ;85(21):11401-8.
Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One. 2011 ;6(1):e16074.
. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One. 2011 ;6(11):e27824.
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol. 2011 ;85(17):8954-67.
A general approach for receptor and antibody-targeted detection of native proteins utilizing split-luciferase reassembly. ACS Chem Biol. 2010 ;5(10):943-52.
. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. J Virol. 2010 ;84(4):1683-95.
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010 ;329(5993):856-61.